Supervised cycling program to ease chemotherapy-related nerve symptoms
Evaluating the Acceptability of a Cycling-Based Aerobic Exercise Intervention for Individuals With Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Study
NA · University of Alberta · NCT07150117
This trial tests if a supervised stationary cycling program can reduce numbness, tingling, and pain in adults with chemotherapy-induced peripheral neuropathy and improve function.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Alberta (other) |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT07150117 on ClinicalTrials.gov |
What this trial studies
This is a 12-week proof-of-concept intervention in which 30 adults with mild (grade 1) chemotherapy-induced peripheral neuropathy will take part in supervised stationary cycling sessions twice weekly, each lasting 30–60 minutes and progressing over time. The study will track feasibility measures (recruitment, adherence, completion, satisfaction, and safety) alongside patient-reported symptoms and objective functional and fitness outcomes. Both patient-reported outcome measures and objective tests will be used to characterize changes in CIPN symptoms and function. Results will inform whether a larger-scale trial is warranted.
Who should consider this trial
Good fit: Adults (18+) with stage I–III cancer who have mild (grade 1) chemotherapy-induced peripheral neuropathy, can read English, are not already in an aerobic training program, and can attend supervised sessions are ideal candidates.
Not a fit: Patients with other causes of neuropathy (for example diabetes), uncontrolled medical conditions, those undergoing surgery or radiation during the study, or those already doing aerobic training are unlikely to benefit from this program.
Why it matters
Potential benefit: If successful, the program could reduce CIPN symptoms like pain and numbness and improve physical function and quality of life.
How similar studies have performed: Multimodal exercise programs have shown promising reductions in CIPN symptoms in prior work, but aerobic-only interventions with objective outcome measures remain relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Cancer diagnosis stage I to III * CIPN: grade 1 (mild) * Receiving or have received chemotherapy treatment for cancer * Speak, read and understand English Exclusion Criteria: * Medical conditions that cause additional neuropathy symptoms (i.e. diabetes) * Any uncontrolled medical conditions * Will undergo surgery or radiation therapy during the study period * Are already receiving an aerobic exercise training program * Are already participating in an exercise-based research study * Are unable to provide signed informed consent
Where this trial is running
Edmonton, Alberta
- Cross Cancer Institute — Edmonton, Alberta, Canada (RECRUITING)
Study contacts
- Principal investigator: Margaret L McNeely, PhD — University of Alberta
- Study coordinator: Christopher Sellar, PhD
- Email: frmace@ualberta.ca
- Phone: 1-780-492-6007
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Adults, peripheral neuropathy, chemotherapy, exercise, aerobic, cancer